FDA expands EUA for Pfizer, Moderna COVID-19 vaccine boosters

By The Science Advisory Board staff writers

November 19, 2021 -- The U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for booster shots of both the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine to include individuals 18 and older.

For the Pfizer-BioNTech vaccine, the booster dose is the same as the doses in the primary series and should be administered at least six months after the primary series was administered, Pfizer said. It was also authorized for use in individuals who completed any other authorized COVID-19 vaccine.

As for the Moderna vaccine, a 50-µg booster dose can be given to all individuals ages 18 and older who have completed primary vaccination with any other authorized or approved COVID-19 vaccine, according to Moderna.

The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices will soon meet to discuss a potential recommendation for the rollout of the Pfizer-BioNTech and Moderna COVID-19 vaccine booster doses.

FDA authorizes COVID-19 vaccine booster shots
Johnson & Johnson and Moderna have received emergency use authorization from the U.S. Food and Drug Administration (FDA) for booster shots of their...
Novavax COVID-19 vaccine booster appears effective after primary vaccination
Novavax announced preliminary data indicating that a single booster dose of the company's recombinant nanoparticle protein-based COVID-19 vaccine drew...
Novavax touts COVID-19 vaccine results
Novavax is highlighting study results that demonstrate the efficacy of its COVID-19 vaccine, NVX-CoV2373, as well as a new COVID-19 vaccine it is developing...
Pfizer to study pneumococcal, COVID-19 vaccine combo in older adults
Pfizer has launched a study that is investigating the coadministration of the company's pneumococcal vaccine (20vPnC) and its Pfizer-BioNTech COVID-19...
Clover highlights preclinical data for COVID-19 vaccine candidate
Clover Biopharmaceuticals said that its second-generation, protein-based COVID-19 vaccine candidate has demonstrated in preclinical testing that it can...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter